Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

Cancer

Volumn 112, Issue 9, 2008, Pages 1941-1948

  Palma, David ^a   Tyldesley, Scott ^a   Pickles, Tom ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Androgen deprivation; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 42449122203     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23388     Document Type: Article

References (19)

1. Maffezzini M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol. 2007;51:605-613.
2. Zhou P, Chen M-H, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23:6992-6998.
3. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294;433-439.
4. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035-2041.
5. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
6. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007;249:30-39.
7. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
8. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174:2191-2196.
9. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447.
10. Palma D, Tyldesley S, Blood P, Liu M, Morris J, Pickles T. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys. 2007;67:1425-1429.
11. Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times; use in patients before radical prostatectomy. J Urol. 1997;158:1876-1878; discussion 1878-1879.
12. Hanks GE, Hanlon AL, Lee WR, Slivjak A, Schultheiss TE. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys. 1996;34:549-553.
13. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001;8:1314-1322.
14. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
15. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
17. D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006;24:4190-4195.
18. D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007;110:56-61.
19. Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: distant metastasis are the cause. Presented at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, Pennsylvania, November 5-9, 2006. Abstract 1132.